AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Microtubule-associated protein RP/EB family member 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q15555

UPID:

MARE2_HUMAN

Alternative names:

APC-binding protein EB2; End-binding protein 2

Alternative UPACC:

Q15555; B2RE21; B3KR39; B4DJV4; B7Z2L3; E9PHR3; F5H1V8; G5E9I6; Q9UQ33

Background:

Microtubule-associated protein RP/EB family member 2, also known as APC-binding protein EB2 and End-binding protein 2, plays a crucial role in microtubule polymerization and spindle function. It stabilizes microtubules and anchors them at centrosomes, which is essential for cell migration. This protein's involvement in these fundamental cellular processes underscores its importance in maintaining cellular integrity and function.

Therapeutic significance:

The protein is linked to the disease 'Skin creases, congenital symmetric circumferential, 2', characterized by multiple skin folds and intellectual disability. Understanding the role of Microtubule-associated protein RP/EB family member 2 could open doors to potential therapeutic strategies for this and related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.